Effect of Angiosonography to Monitor Response During Imatinib Treatment in Patients with Metastatic Gastrointestinal Stromal Tumors
Open Access
- 1 September 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (17) , 6171-6176
- https://doi.org/10.1158/1078-0432.ccr-04-2046
Abstract
Purpose: Gastrointestinal stromal tumor (GIST) metastases are typically intra-abdominal and hypervascular. We assessed the effect of angiosonography with a second-generation contrast agent to monitor response during imatinib treatment in patients with metastatic KIT+ GIST.Keywords
This publication has 13 references indexed in Scilit:
- Gastrointestinal Stromal Tumor: New Nodule-within-a-Mass Pattern of Recurrence after Partial Response to Imatinib MesylateRadiology, 2005
- Imatinib and gastrointestinal stromal tumors: Where do we go from here?Molecular Cancer Therapeutics, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemiaBlood, 2004
- Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinibBlood, 2004
- Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor ExpressionJNCI Journal of the National Cancer Institute, 2004
- STI-571 inhibits in vitro angiogenesisBiochemical and Biophysical Research Communications, 2003
- Pharmacology of imatinib (STI571)European Journal Of Cancer, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- BR1: A New Ultrasonographic Contrast Agent Based on Sulfur Hexafluoride-Filled MicrobubblesInvestigative Radiology, 1995